FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Steven P. Treon, MD, PhD: Waldenström macroglobulinemia is an indolent non-Hodgkin lymphoma. It’s an interesting disease that shares many features of mature lymphomas as well as plasma cell dyscrasias ...
MB-106, a CD20-targeted CAR-T cell therapy, received orphan drug designation for Waldenstrom macroglobulinemia, a rare blood cancer. The Orphan Drug Act incentivizes drug development for rare diseases ...
Ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years, research concludes. The disease ...
A new study by researchers at Winship Cancer Institute of Emory University finds that cancer-associated mutations originate in blood progenitor cells, leading to distinct changes in both cancer and ...
Ibrutinib (Imbruvica, Pharmacyclics) has become the first drug for the treatment of Waldenstrom's macroglobulinemia, a rare, indolent type of B-cell lymphoma, to be approved by the US Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results